KR102491017B1 - Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient - Google Patents
Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient Download PDFInfo
- Publication number
- KR102491017B1 KR102491017B1 KR1020210128268A KR20210128268A KR102491017B1 KR 102491017 B1 KR102491017 B1 KR 102491017B1 KR 1020210128268 A KR1020210128268 A KR 1020210128268A KR 20210128268 A KR20210128268 A KR 20210128268A KR 102491017 B1 KR102491017 B1 KR 102491017B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- extract
- true
- coral
- glycation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 239000004480 active ingredient Substances 0.000 title claims abstract description 12
- 230000003020 moisturizing effect Effects 0.000 title abstract description 23
- 230000003064 anti-oxidating effect Effects 0.000 title abstract description 8
- 241001474374 Blennius Species 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 title description 4
- 230000001153 anti-wrinkle effect Effects 0.000 title 1
- 241000206575 Chondrus crispus Species 0.000 claims abstract description 71
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 claims abstract description 64
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims abstract description 58
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims abstract description 58
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims abstract description 58
- 230000037303 wrinkles Effects 0.000 claims abstract description 24
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 20
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract description 19
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims abstract description 19
- 230000008929 regeneration Effects 0.000 claims abstract description 19
- 238000011069 regeneration method Methods 0.000 claims abstract description 19
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 206010072170 Skin wound Diseases 0.000 claims abstract description 13
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims abstract description 13
- 229940099552 hyaluronan Drugs 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 9
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 89
- 235000014653 Carica parviflora Nutrition 0.000 claims description 63
- 241000243321 Cnidaria Species 0.000 claims description 62
- 239000002537 cosmetic Substances 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 15
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 12
- 230000001737 promoting effect Effects 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 abstract description 63
- 230000000694 effects Effects 0.000 abstract description 47
- 230000006872 improvement Effects 0.000 abstract description 22
- 210000004927 skin cell Anatomy 0.000 abstract description 13
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 abstract description 10
- 239000013642 negative control Substances 0.000 abstract description 10
- 241001491621 Corallina officinalis Species 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 230000003078 antioxidant effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 13
- 230000002500 effect on skin Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- -1 nicotinoyl Chemical group 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 230000036252 glycation Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000002000 scavenging effect Effects 0.000 description 9
- 230000036560 skin regeneration Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 210000001626 skin fibroblast Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 201000001117 malignant triton tumor Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- VVTDHOIRNPCGTH-NSHDSACASA-N Mycosporine Chemical compound COC1=C(NC(CO)CO)C[C@@](O)(CO)CC1=O VVTDHOIRNPCGTH-NSHDSACASA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- VIZAVBQHHMQOQF-KKUJBODISA-N porphyra-334 Chemical compound COC1=C(NCC(O)=O)CC(O)(CO)C\C1=N\[C@H]([C@H](C)O)C(O)=O VIZAVBQHHMQOQF-KKUJBODISA-N 0.000 description 2
- VIZAVBQHHMQOQF-UHFFFAOYSA-N porphyra-334 Natural products COC1=C(CC(O)(CO)C/C/1=NC(C(C)O)C(=O)O)NCC(=O)O VIZAVBQHHMQOQF-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 1
- LDWBQGACJJOIKA-RHEFHGCGSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O LDWBQGACJJOIKA-RHEFHGCGSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QUOANUOITQPOFA-UHFFFAOYSA-M 2-(2,5-diphenyltetrazol-1-ium-1-yl)-4-methyl-1,3-thiazole;bromide Chemical compound [Br-].CC1=CSC([N+]=2N(N=NC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 QUOANUOITQPOFA-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OTZURLUZDRIZEM-JYRVWZFOSA-N Asterina 330 Natural products COC1=C(CC(O)(CO)C/C/1=N/CCO)NCC(=O)O OTZURLUZDRIZEM-JYRVWZFOSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- SZEOBSAZWJLOGY-VGMNWLOBSA-N Glycylprolylhydroxyproline Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)C[C@@H](O)C1 SZEOBSAZWJLOGY-VGMNWLOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000000212 ceratonia siliqua l. fruit extract Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- QMIFIFIYYPUVNU-ACMTZBLWSA-L copper (2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-imidazol-1-id-4-ylpropanoyl]amino]hexanoate Chemical compound [Cu+2].NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=C[N-]C=N1 QMIFIFIYYPUVNU-ACMTZBLWSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 108010056686 glycosylated collagen Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- OMPMQQQHTAPTHR-UHFFFAOYSA-N usujirene Natural products COC1=C(CC(O)(CO)C/C/1=NC=C/C)NCC(=O)O OMPMQQQHTAPTHR-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 해조류 및 펩타이드를 유효성분으로 포함하는 항당화, 항산화, 피부 주름 개선 및 피부 보습용 조성물에 관한 것으로, 더욱 상세히는 아이리쉬 모스, 참산호말 및 아세틸헥사펩타이드-8의 3종 복합성분을 유효성분으로 포함하는 항당화, 항산화, 피부 주름 개선 및 피부 보습용 조성물에 관한 것이다.The present invention relates to a composition for anti-glycation, anti-oxidation, skin wrinkle improvement and skin moisturizing, containing seaweed and peptides as active ingredients, and more specifically, three complex components of Irish moss, true coral and acetyl hexapeptide-8 It relates to a composition for anti-glycation, anti-oxidation, skin wrinkle improvement and skin moisturizing comprising as an active ingredient.
당화(Glycation)는 일반적으로 효소의 관여 없이 일어나는 단백질 또는 지방에 포도당 또는 과당과 같은 단순당이 공유결합을 형성하는 반응을 의미한다. 당화는 일련의 아마도리 전위(Amadori rearrangement), 마이야르 반응(Maillard Reaction)으로 알려진 복잡한 화학적 반응을 거쳐 일어나게 되며, 그 결과 최종당화산물(AGEs: Advanced glycation endproducts)이 생성된다.Glycation generally refers to a reaction in which a simple sugar such as glucose or fructose forms a covalent bond with a protein or fat that occurs without the involvement of enzymes. Glycation occurs through a series of complex chemical reactions known as Amadori-rearrangements and Maillard-reactions, resulting in advanced glycation endproducts (AGEs).
한편, 단백질의 당화 과정은 효소 작용이 관여하지 않아 천천히 일어나게 되고, 콜라겐과 같이 반감기가 긴 구조 단백질에서 더욱 많은 영향을 끼치게 된다. 최종당화산물을 분석한 결과 나이가 많을수록 당화된 콜라겐이 축적되는 양상을 보였으며, 최종당화산물이 축적된 단백질을 단단하고 더욱 부서지기 쉬운 상태로 변화된다. 이렇게 당화된 콜라겐은 진피층의 세포 외 기질에서 적절한 구조를 형성하지 못하게 되며, 피부의 탄력을 잃게 하고 주름 생성을 촉진하는 원인으로 보고되고 있다(Dyer, D. G. et al., The Journal of Clinical Investigation, 9, p. 2463, 1993).On the other hand, the glycosylation process of protein occurs slowly because enzyme action is not involved, and it has a greater effect on structural proteins with a long half-life, such as collagen. As a result of the analysis of advanced glycation end products, it was shown that the older the age, the more glycated collagen was accumulated, and the accumulated glycated end products changed into a hard and more brittle state. Glycosylated collagen fails to form an appropriate structure in the extracellular matrix of the dermal layer, and is reported to be a cause of losing skin elasticity and promoting wrinkle formation (Dyer, D. G. et al., The Journal of Clinical Investigation, 9 , p. 2463, 1993).
또한, 당화로 인해 생성된 최종당화산물은 갈색을 띠는 물질로써 피부 노화가 진행됨에 따라 진피층 상부에 쌓이는 것으로 알려져 있다. 피부 노화가 진행되면서 점차 얼굴빛이 노랗게 변하는 원인 물질로 생각되고 있으며, 특정 최종당화산물이 쌓일수록 피부에서 반사되는 반사 빛이 줄어든다고 알려져 있다. 피부 속 멜라닌 색소의 양은 피부 노화와 상관 관계가 약한 반면, 피부 진피층에 쌓이는 최종당화산물은 피부 노화가 진행됨에 따라 점차 그 양이 늘어나게 되고 얼굴빛을 어둡게 만들 수 있다(Hiroshi, O. et al., Skin Research and Technology, 15, p. 96, 2009).In addition, it is known that the final glycation products produced by glycation are brownish substances and accumulate in the upper dermal layer as skin aging progresses. It is thought to be a causative substance that gradually turns yellow as skin aging progresses, and it is known that as specific final saccharification products accumulate, reflected light from the skin decreases. While the amount of melanin pigment in the skin has a weak correlation with skin aging, the amount of advanced glycation products accumulated in the dermal layer of the skin gradually increases as skin aging progresses and can darken the complexion (Hiroshi, O. et al., Skin Research and Technology, 15, p. 96, 2009).
당화를 억제하는 물질로 아미노구아니딘(Aminoguanidine), 피리독사민(Pyridoxamine), 아스피린(Aspirin) 등이 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 효과를 기대할 수 없는 문제점이 있다.Aminoguanidine, Pyridoxamine, and Aspirin are known as substances that inhibit glycation, but these substances have limitations in usage due to safety issues on the skin, or are ineffective due to insignificant effects. There are problems that cannot be expected.
한편, 화장품 소재는 안전성, 효능, 물성 등이 균형을 이루어야 한다. 또한 경제성 확보도 중요한 요인으로서 화장품용 소재는 다양한 개발 방법, 천연물 추출과 미생물 등에 의한 발효를 이용하여 피부 투과, 노화 억제, 생리활성, 안전성 및 물성을 최적화하여 개발하게 된다. 화장품과 의약품의 경계가 무너지면서 화장품의 안정성과 의약품의 효과성을 겸비한 복합 기능성 원료 및 바이오 소재를 통해 다양한 코스메슈티컬 제품들이 높은 성장세를 이어가고 있다. On the other hand, cosmetic materials must balance safety, efficacy, and physical properties. In addition, securing economic feasibility is also an important factor, and cosmetic materials are developed by optimizing skin permeation, aging inhibition, physiological activity, safety, and physical properties using various development methods, natural product extraction and fermentation by microorganisms. As the boundary between cosmetics and pharmaceuticals is collapsing, various cosmeceutical products continue to grow rapidly through complex functional raw materials and bio-materials that combine the stability of cosmetics and the effectiveness of pharmaceuticals.
이러한 배경 아래에서, 본 발명자들은 항당화에 효과가 우수한 천연물 소재의 발굴을 위해 예의 연구 노력하였고, 천연 해조류 성분들을 조합하여 이들이 갖는 항당화 효능을 강화하기 위해 다양한 연구를 시도한 결과, 아이리쉬 모스와 참산호말의 2종 성분과 아세틸헥사펩타이드-8을 조합하는 경우 항당화능이 유의하게 개선되는 한편, 항산화, 피부 주름 개선, 보습, 및 피부 재생 활성에도 우수한 효과를 있음을 규명하여, 본 발명을 완성하게 되었다.Under this background, the present inventors have made diligent research efforts to discover natural materials that are effective in antiglycation, and as a result of various studies to enhance their antiglycation efficacy by combining natural seaweed components, Irish Moss and Cham The present invention was completed by finding that the antiglycation ability was significantly improved when two components of coral powder were combined with acetyl hexapeptide-8, while antioxidation, skin wrinkle improvement, moisturizing, and skin regeneration activity were also excellent. I did.
따라서, 본 발명의 주된 목적은 항당화, 항산화, 피부 주름 개선, 피부 보습 및 피부 재생 촉진에 뛰어난 효과가 있는 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분을 유효성분으로 함유하는 조성물을 제공하는 데 있다. Therefore, the main object of the present invention is to use the three complex components of Irish moss extract, true coral extract and acetyl hexapeptide-8, which have excellent effects on antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing and skin regeneration, as active ingredients. It is to provide a composition containing as.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명의 한 양태에 따르면, 본 발명은 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분을 유효성분으로 포함하되, 상기 3종 복합성분은 10:5~15:2.5~7.5의 중량비로 구성된 것을 특징으로 하는 항당화, 항산화, 피부 주름 개선 및 피부 보습용 화장료 조성물을 제공한다.According to one aspect of the present invention, the present invention includes three complex components of Irish Moss extract, true coral extract, and acetyl hexapeptide-8 as active ingredients, wherein the three complex components are 10:5 to 15:2.5 It provides a cosmetic composition for anti-glycation, antioxidant, skin wrinkle improvement and skin moisturizing, characterized in that it is composed of a weight ratio of ~ 7.5.
본 발명자들은 항당화, 항산화, 피부 주름 개선, 피부 보습, 피부 재생 촉진 등 피부 상태 개선에 우수한 효과를 보유한 천연 추출물을 찾기 위한 연구를 수행하였으며, 특히 천연 해조류를 활용하여 항당화능을 더욱 개선시키고자 예의 연구노력한 결과, 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8로 구성된 3종 복합성분을 10:5~15:2.5~7.5의 중량비로 배합하는 경우, 우수한 항당화, 항산화, 피부 주름 개선, 피부 보습, 및 피부 재생 촉진 활성을 갖는 것을 확인하였고, 또한 피부에 적용시에도 안전성에 문제가 없음을 확인하였다.The present inventors conducted research to find natural extracts with excellent effects on skin condition improvement, such as anti-glycation, anti-oxidation, skin wrinkle improvement, skin moisturization, and skin regeneration promotion. As a result of diligent research efforts, when three complex ingredients consisting of Irish Moss extract, true coral extract and acetyl hexapeptide-8 are combined in a weight ratio of 10:5~15:2.5~7.5, excellent antiglycation, antioxidant, and skin It was confirmed that it has wrinkle improvement, skin moisturizing, and skin regeneration promoting activities, and it was also confirmed that there is no safety problem when applied to the skin.
본 발명의 상기 아이리쉬 모스(Chondrus Crispus)는 돌가사리과 카라긴속에 속하는 해조류로, 카라긴(carraigin)으로도 불리우며, 유럽과 북아메리카의 대서양 해안 암석지대에 자라는 홍조류이다. 아이리쉬 모스는 Porphyra-334, Palythene 등 MAA(Mycosporine like Amino Acids) 성분들을 다량 포함하는 것을 특징으로 한다. The Irish Moss ( Chondrus Crispus ) of the present invention is a seaweed belonging to the genus Dolphinaceae Carragin, also called carraigin, and is a red algae that grows in rocky areas of the Atlantic coast of Europe and North America. Irish Moss is characterized by containing a large amount of MAA (Mycosporine like Amino Acids) ingredients such as Porphyra-334 and Palythene.
또한, 상기 참산호말(Corallina Officinalis)은 지누아리목 산호말과에 속하는 홍조류로, 우리나라 동해안, 울릉도 등지에 분포하며, Asterina-330, Porphyra-334 등 MAA(Mycosporine like Amino Acids) 성분들을 다량 포함하는 것을 특징으로 한다. In addition, the true coral ( Corallina Officinalis ) is a red algae belonging to the order Jinuari, distributed in the east coast of Korea and Ulleungdo, etc., and contains a large amount of MAA (Mycosporine like Amino Acids) components such as Asterina-330 and Porphyra-334. It is characterized by doing.
또한, 아세틸헥사펩타이드-8(Acetyl Hexapeptide-8)(CAS NO. 616204-22-9)은 하기 화학식 1의 화학식 구조를 갖는 펩타이드 성분으로, 화장품 원료 성분으로 등재된 물질이다. In addition, Acetyl Hexapeptide-8 (CAS NO. 616204-22-9) is a peptide component having the chemical structure of
[화학식 1][Formula 1]
본 발명의 상기 아세틸헥사펩타이드-8은 아이리쉬 모스 및 참산호말과 조합하여 항당화, 항산화, 피부 주름 개선, 피부 보습, 및 피부 재생 촉진 활성을 더욱 개선하는 효과가 있다. 상기 아세틸헥사펩타이드-8과 유사한 작용을 하는 펩타이드로 카퍼트라이펩타이드-1, 트라이펩타이드-29, 트라이펩타이드-1, 헥사펩타이드-12, 니코티노일트라이펩타이드-35, 팔미토일트라이펩타이드-1, 팔미토일펜타펩타이드-4, 노나펩타이드-7, 팔미토일트라이펩타이드-29, 팔미토일테트라펩타이드-7, 헥사펩타이드-9 등의 펩타이드가 있으나, 가장 바람직하게는 아세틸헥사펩타이드-8을 사용하는 것이 아이리쉬 모스 및 참산호말과 조합하여 항당화, 항산화, 피부 주름 개선, 피부 보습, 및 피부 재생 촉진 활성에 있어 가장 우수한 시너지 효과를 나타낼 수 있다. The acetyl hexapeptide-8 of the present invention has effects of further improving antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing, and skin regeneration promoting activity in combination with Irish moss and true coral. Copper tripeptide-1, tripeptide-29, tripeptide-1, hexapeptide-12, nicotinoyl tripeptide-35, palmitoyl tripeptide-1, palmitoyl tripeptide-1, palmitoyl tripeptide-1 There are peptides such as Toyl Pentapeptide-4, Nonapeptide-7, Palmitoyl Tripeptide-29, Palmitoyl Tetrapeptide-7, and Hexapeptide-9, but most preferably Acetyl Hexapeptide-8 is used. And it can show the best synergistic effect in antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing, and skin regeneration promoting activity in combination with true coral.
본 발명자들은 천연 해조류 성분들의 항당화 효과를 더욱 개선시키기 위해 이들의 조합 및 조합 비율에 대한 연구를 심층적으로 진행하는 과정에서 상기 아이리쉬 모스(Chondrus Crispus) 및 참산호말(Corallina Officinalis)과 아세틸헥사펩타이드-8(Acetyl Hexapeptide-8)을 조합하여 사용하는 경우, 일정 수준 이상의 시너지 효과가 있는 것을 확인하였고, 상기 3종 복합성분을 10:5~15:2.5~7.5의 중량비로 배합하는 경우, 항당화, 항산화, 피부 주름 개선, 피부 보습, 및 피부 재생 촉진에 우수한 활성을 나타내는 것을 확인하였으며, 가장 바람직하게는 상기 3종 복합성분을 10:10:5의 중량비로 배합하는 경우, 항당화, 항산화, 피부 주름 개선, 피부 보습, 및 피부 재생 촉진 활성이 극대화되는 것을 확인한 바 있다.In order to further improve the antiglycation effect of natural seaweed components, the present inventors conducted in-depth research on their combinations and combination ratios, and found that the Irish Moss ( Chondrus Crispus ) and true corals ( Corallina Officinalis ) and acetyl hexapeptide When -8 (Acetyl Hexapeptide-8) is used in combination, it was confirmed that there is a synergistic effect of a certain level or more, and when the above three complex components are combined at a weight ratio of 10:5 to 15:2.5 to 7.5, antiglycation . It has been confirmed that the activities of improving skin wrinkles, moisturizing skin, and promoting skin regeneration are maximized.
본 발명에서 사용되는 용어, "추출물"은 아이리쉬 모스(Chondrus Crispus) 및/또는 참산호말(Corallina Officinalis)의 추출 처리로 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 본 발명의 상기 추출물은 바람직하게 추출 후 건조 분말 형태로 제조되어 사용될 수 있다. 상기 아이리쉬 모스(Chondrus Crispus) 및/또는 참산호말(Corallina Officinalis)의 추출에 있어서, 상기 추출물을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 추출방법을 병용하여 수행될 수 있다. As used herein, the term "extract" refers to an extract obtained by extraction of Irish moss ( Chondrus Crispus ) and / or true coral ( Corallina Officinalis ), a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, and the above It includes extracts of all formulations that can be formed using the extract itself and the extract, such as a refined product or a purified product of the extract, or a mixture thereof. The extract of the present invention may be preferably prepared and used in the form of a dry powder after extraction. In the extraction of the Irish Moss ( Chondrus Crispus ) and / or true coral ( Corallina Officinalis ), a method for extracting the extract is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination with two or more extraction methods.
본 발명에서 상기 아이리쉬 모스(Chondrus Crispus) 및 참산호말(Corallina Officinalis)을 추출하는데 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 C1 내지 C4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게, 물, 저급알코올, 1,3-부틸렌글리콜, 에틸아세테이트를 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있다. In the present invention, the type of extraction solvent used to extract the Irish Moss ( Chondrus Crispus ) and true coral ( Corallina Officinalis ) is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent include water; C1 to C4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture thereof may be used, and preferably, water, lower alcohol, 1,3-butylene glycol, and ethyl acetate may be used alone or in combination of two or more.
본 발명에서 열수 추출 또는 냉침 추출한 추출물은 부유하는 고체 입자를 제거하기 위해 여과, 예를 들어 나일론 등을 이용해 입자를 걸러내거나 냉동여과법 등을 이용해 여과한 후, 그대로 사용하거나 이를 동결건조, 열풍건조, 분무건조 등을 이용해 건조하여 사용할 수 있다.In the present invention, the extract obtained by hot water extraction or cold brewing is filtered to remove floating solid particles by filtering out the particles using, for example, nylon or by using cryofiltration, and then used as it is or freeze-dried, hot-air-dried, It can be used after being dried using spray drying or the like.
본 발명에서 사용되는 용어, "분획물"은 여러 다양한 구성성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다. As used herein, the term "fraction" refers to a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
상기 분획 방법의 비제한적인 예로는, 아이리쉬 모스(Chondrus Crispus) 및/또는 참산호말(Corallina Officinalis)를 추출하여 얻은 추출물에 소정의 용매를 처리하여 상기 추출물로부터 분획물을 얻는 방법을 들 수 있다. 본 발명에서 상기 분획물을 얻는 데에 사용되는 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매의 비제한적인 예로는 물, 알코올 등의 극성 용매; 헥산(Hexane), 에틸아세테이트(Ethyl acetate), 클로로포름(Chloroform), 디클로로메탄(Dichloromethane) 등의 비극성 용매 등을 들 수 있다. 이들은 단독으로 사용되거나 2종 이상 혼합하여 사용될 수 있다. 상기 분획 용매 중 알코올을 사용하는 경우에는 구체적으로는 C1 내지 C4의 알코올을 사용할 수 있다.Non-limiting examples of the fractionation method include a method of obtaining fractions from the extract by treating an extract obtained by extracting Irish Moss ( Chondrus Crispus ) and/or true coral ( Corallina Officinalis ) with a predetermined solvent. In the present invention, the type of solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more. When alcohol is used among the fractionation solvents, C1 to C4 alcohols may be specifically used.
본 발명의 화장료 조성물은 상기 아이리쉬 모스(Chondrus Crispus) 및 참산호말(Corallina Officinalis) 추출물에 아세틸헥사펩타이드-8(Acetyl Hexapeptide-8)을 조합하여 사용할 수 있는데, 상기 성분들을 조합하는 경우, 조합비는 특별히 이에 제한되지 않으나, 바람직하게는 10:5~15:2.5~7.5의 중량비로 조합하여 사용할 수 있고, 가장 바람직하게는 10:10:5의 중량비로 조합하여 사용할 수 있다. The cosmetic composition of the present invention can be used by combining Acetyl Hexapeptide-8 with the Irish Moss ( Chondrus Crispus ) and true coral ( Corallina Officinalis ) extracts. It is not particularly limited thereto, but preferably may be used in combination at a weight ratio of 10:5 to 15:2.5 to 7.5, and most preferably may be used in combination at a weight ratio of 10:10:5.
본 발명의 화장료 조성물에서, 상기 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분은 활성산소종(ROS, Reactive Oxygen Species)을 소거하고, MMP-1 단백질의 발현 억제를 통해 피부 주름 생성을 억제하며, 히알루론산(Hyaluronan) 합성을 촉진하여 피부 보습 활성을 나타내는 것을 특징으로 한다. 본 발명의 바람직한 실시예에서는 이들 3종 성분이 10:5~15:2.5~7.5의 중량 비율로 혼합되는 경우 대표적인 항당화 물질로 알려진 아미노구아니딘과 동등 이상의 항당화 활성을 나타내고(도 2 참조), 자외선 무처리 음성대조군과 유사한 수준의 우수한 활성산소종 소거 활성을 나타내며(도 3 참조), MMP-1 단백질 발현을 현저하게 억제하고(도 4 참조), 피부 세포에서 히알루론산(Hyaluronan)의 합성을 효과적으로 증가시키는 것을 확인한 바 있다(도 5 참조). In the cosmetic composition of the present invention, the three complex components of the Irish moss extract, the true coral extract, and acetyl hexapeptide-8 scavenge reactive oxygen species (ROS) and inhibit the expression of MMP-1 protein. It is characterized in that it suppresses the formation of skin wrinkles and promotes the synthesis of hyaluronic acid to exhibit skin moisturizing activity. In a preferred embodiment of the present invention, when these three components are mixed in a weight ratio of 10:5 to 15:2.5 to 7.5, they exhibit antiglycation activity equal to or higher than that of aminoguanidine, known as a representative anti-glycation substance (see FIG. 2), It exhibits excellent reactive oxygen species scavenging activity similar to that of the negative control group without UV treatment (see FIG. 3), significantly inhibits MMP-1 protein expression (see FIG. 4), and inhibits the synthesis of hyaluronan in skin cells. It has been confirmed that it increases effectively (see FIG. 5).
또한, 본 발명의 화장료 조성물에서, 상기 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분은 피부 상처 재생 촉진에 우수한 활성을 나타내는 것을 특징으로 한다. 본 발명의 바람직한 실시예에서는 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 3종 복합성분을 손상된 피부세포에 처리하는 경우, 손상된 피부세포 재생이 직접적으로 촉진되는 것을 확인할 수 있었으며, 이러한 효과는 10:5~15:2.5~7.5의 중량비에서 더욱 우수한 것을 확인한 바 있다(도 6 참조). In addition, in the cosmetic composition of the present invention, the three complex components of the Irish moss extract, true coral extract, and acetyl hexapeptide-8 are characterized by exhibiting excellent activity in promoting skin wound regeneration. In a preferred embodiment of the present invention, it was confirmed that when damaged skin cells were treated with three complex components of Irish Moss extract, true coral malt, and acetylhexapeptide-8, regeneration of damaged skin cells was directly promoted, and these effects has been confirmed to be more excellent at a weight ratio of 10:5 to 15:2.5 to 7.5 (see FIG. 6).
본 발명의 화장료 조성물은 천연 해조류 소재에서 유래한 아이리쉬 모스 추출물 및 참산호말 추출물과, 피부 부작용이 없는 안전한 소재로 알려진 아세틸헥사펩타이드-8의 3종 복합성분을 조합하여 인체에 해가 없으며, 그 첨가로 인해 화장품의 물질의 품질을 손상하지 않으므로 화장료 조성물에 포함되어 사용되는데 적합하다. 특히, 항당화, 항산화, 피부 주름 개선, 피부 보습, 및 피부 상처 재생 촉진과 관련된 기능이 있으므로, 기능성 화장료 조성물에 포함되어 사용되는 것이 바람직하다.The cosmetic composition of the present invention is harmless to the human body by combining three complex components: Irish moss extract and true coral extract derived from natural seaweed materials, and acetyl hexapeptide-8, known as a safe material without skin side effects. Since it does not impair the quality of the material of cosmetics due to addition, it is suitable for being used in a cosmetic composition. In particular, since it has functions related to antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing, and skin wound regeneration promotion, it is preferable to be included in a functional cosmetic composition and used.
본 발명의 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 마사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 마스크팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저에서 선택된 어느 하나의 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention is skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture cream, hand cream, foundation, essence, nutrient essence, mask pack, It may be prepared in any one formulation selected from soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
본 발명의 상기 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면 활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and as typical ingredients, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners , A chelating agent, a colorant, a preservative, a flavoring agent, etc. may be appropriately mixed, but is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 화장료 조성물의 제형에 따라 다양하다.Cosmetically acceptable carriers included in the cosmetic composition of the present invention vary depending on the formulation of the cosmetic composition.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. This may be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 등이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로하드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohard propellants such as, but not limited to, low carbon, propane/butane or dimethyl ether. These may be used alone or in combination of two or more.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제 등이 이용될 수 있으며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일 등이 이용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil and the like may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan Can be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타하이드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a suspension, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 비누인 경우에는, 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugar, etc. are used as carrier components. It may be, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 화장료 조성물에서, 상기 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분은 구체적으로는 건조 중량으로, 화장료 조성물 총 중량의 0.001 중량% 내지 50 중량%로 포함될 수 있으며, 보다 구체적으로는 0.005 중량% 내지 10 중량%로 포함될 수 있다. 상기 범위 내에서 항당화, 항산화, 피부 주름 개선, 피부 보습, 및 피부 상처 재생 촉진에 대한 우수한 효능을 나타내는 이점이 있으며, 조성물의 제형이 안정화되는 이점이 있다.In the cosmetic composition of the present invention, the three complex components of the Irish Moss extract, true coral extract, and acetyl hexapeptide-8 are specifically dry weight, 0.001% to 50% by weight of the total weight of the cosmetic composition. And, more specifically, it may be included in 0.005% by weight to 10% by weight. Within the above range, there is an advantage of exhibiting excellent efficacy for antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing, and promotion of skin wound regeneration, and there is an advantage that the formulation of the composition is stabilized.
본 발명의 다른 양태에 따르면, 본 발명은 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분을 유효성분으로 포함하되, 상기 3종 복합성분은 10:5~15:2.5~7.5의 중량비로 구성된 것을 특징으로 하는 항당화, 항산화, 피부 주름 개선 및 피부 보습용 식품 조성물을 제공한다. According to another aspect of the present invention, the present invention includes three complex components of Irish moss extract, true coral extract, and acetylhexapeptide-8 as active ingredients, wherein the three complex components are 10:5 to 15:2.5 It provides a food composition for anti-glycation, antioxidant, skin wrinkle improvement and skin moisturizing, characterized in that it consists of a weight ratio of ~ 7.5.
본 발명의 상기 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분은 10:5~15:2.5~7.5의 중량 비율에서 대표적인 항당화 물질로 알려진 아미노구아니딘과 동등 이상의 항당화 활성을 나타내고, 자외선 무처리 음성대조군과 유사한 수준의 우수한 활성산소종 소거 활성을 나타내며, MMP-1 단백질 발현을 현저하게 억제하고, 피부 세포에서 히알루론산(Hyaluronan)의 합성을 효과적으로 증가시키며, 피부 상처 재생에 우수한 활성을 나타내므로, 항당화, 항산화, 피부 주름 개선, 피부 보습 및 피부 상처 재생과 관련된 피부 상태의 개선을 위한 식품 조성물로 유용하게 사용될 수 있다. The three complex components of the Irish Moss extract, true coral extract, and acetylhexapeptide-8 of the present invention have antiglycation equivalent to or better than aminoguanidine, known as a representative antiglycation substance, at a weight ratio of 10:5 to 15:2.5 to 7.5. activity, exhibits excellent reactive oxygen species scavenging activity similar to that of the UV-untreated negative control group, significantly inhibits MMP-1 protein expression, effectively increases the synthesis of hyaluronan in skin cells, and improves skin wounds Since it exhibits excellent activity in regeneration, it can be usefully used as a food composition for improving skin conditions related to antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing and skin wound regeneration.
본 발명의 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분과 항당화, 항산화, 피부 주름 개선, 피부 보습 및 피부 상처 재생촉진에 대한 효과는 상기에서 설명한 바와 같다. 상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되는 것은 아니다. The three complex components of the present invention, Irish moss extract, true coral extract, and acetyl hexapeptide-8, and their effects on antiglycation, antioxidant, skin wrinkle improvement, skin moisturization, and promotion of skin wound regeneration are as described above. The food composition may be used in the form of health functional food, but is not limited thereto.
본 발명의 식품 조성물은 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분에 대한 분획물 또는 이의 가공물의 형태로 포함될 수 있다. 또한, 상기 조성물은 유효성분 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The food composition of the present invention may be included in the form of a fraction or a processed product thereof for the three complex components of Irish Moss extract, true coral extract and acetylhexapeptide-8. In addition, the composition may include a food additive that is acceptable in food science in addition to the active ingredient.
본 발명에 있어서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.In the present invention, "food supplement additive" refers to a component that can be added to food supplementally, and can be appropriately selected and used by those skilled in the art as being added to prepare a health functional food of each formulation. Examples of food additives include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners , pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. are included, but the types of food additives of the present invention are not limited by the above examples.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻는 것을 의미하며, 구체적으로 항당화, 항산화, 피부 주름 개선, 피부 보습 및 피부 상처 재생촉진 효과를 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법으로 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. The food composition of the present invention may include health functional food. In the present invention, "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functionality for the human body. Here, "functionality" means adjusting nutrients for the structure and function of the human body or obtaining useful effects for health purposes such as physiological actions, etc., specifically antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing and skin wounds. means a regenerative effect. The health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation.
또한, 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식용가능한 식물 추출물을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나며, 아미노구아니딘과 동등 이상의 항당화 활성을 나타내고, 자외선 무처리 음성대조군과 유사한 수준의 우수한 활성산소종 소거 활성을 나타내며, MMP-1 단백질 발현을 현저하게 억제하고, 피부 세포에서 히알루론산(Hyaluronan)의 합성을 효과적으로 증가시키며, 피부 상처 재생에 우수한 활성을 나타내므로, 이들 효과를 얻기 위한 보조제로 섭취할 수 있다.In addition, the formulation of the health functional food may also be manufactured without limitation as long as the formulation is recognized as a health functional food. The food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time by using edible plant extracts as raw materials, and has excellent portability, It exhibits antiglycation activity equal to or higher than that of aminoguanidine, exhibits excellent reactive oxygen species scavenging activity similar to that of the UV untreated negative control group, significantly suppresses MMP-1 protein expression, and synthesizes hyaluronan in skin cells. It effectively increases and exhibits excellent activity in skin wound regeneration, so it can be taken as an adjuvant to obtain these effects.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용하여 사용할 수 있다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 성분을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한, 동물을 위한 사료로 이용되는 식품도 포함된다.There is no limit to the form that the health functional food of the present invention can take, and it may include all foods in a conventional sense, and may be used interchangeably with terms known in the art, such as functional foods. In addition, the health functional food of the present invention may be prepared by mixing suitable other auxiliary ingredients and known additives that may be included in food according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There is a vitamin complex, etc., and it can be prepared by adding the three components of Irish moss extract, true coral extract and acetyl hexapeptide-8 according to the present invention to juice, tea, jelly, juice, etc. prepared as main components. Also included are foods used as feed for animals.
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(1) 본 발명은 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 3종 복합성분을 유효성분으로 포함하는 항당화, 항산화, 피부 주름 개선 및 피부 보습용 화장료 조성물을 제공한다.(1) The present invention provides a cosmetic composition for anti-glycation, anti-oxidation, skin wrinkle improvement and skin moisturizing, comprising three complex components of Irish moss extract, true coral extract, and acetyl hexapeptide-8 as active ingredients.
(2) 본 발명의 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8로 구성된 3종 복합성분은 세포 독성이 없고, 대표적인 항당화 물질로 알려진 아미노구아니딘과 동등 이상의 항당화 활성을 나타내며, 자외선 무처리 음성대조군과 유사한 수준의 우수한 활성산소종 소거 활성을 나타내고, MMP-1 단백질 발현을 현저하게 억제하며, 피부 세포에서 히알루론산(Hyaluronan)의 합성을 효과적으로 증가시키고, 피부 상처 재생에 우수한 활성을 나타내므로, 화장품, 식품, 및 의약품 분야에서 항당화, 항산화, 피부 주름 개선, 피부 보습 및 피부 상처 재생의 목적으로 유용하게 이용 가능하다.(2) The three complex components composed of Irish moss extract, true coral extract, and acetyl hexapeptide-8 of the present invention have no cytotoxicity, show antiglycation activity equal to or higher than aminoguanidine known as a representative antiglycation substance, and It exhibits excellent reactive oxygen species scavenging activity similar to that of the untreated negative control group, significantly inhibits MMP-1 protein expression, effectively increases the synthesis of hyaluronan in skin cells, and has excellent activity in skin wound regeneration. Therefore, it can be usefully used for the purpose of antiglycation, antioxidant, skin wrinkle improvement, skin moisturizing and skin wound regeneration in cosmetics, food, and pharmaceutical fields.
(3) 또한, 본 발명의 조성물은 인체에 매우 안전할 뿐만 아니라, 안정성도 매우 탁월하다.(3) In addition, the composition of the present invention is not only very safe to the human body, but also has excellent stability.
도 1은 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 단일 또는 복합성분을 인간피부섬유아세포(NHDF, normal human dermal fibroblasts)에 처리하고, 세포 생존률을 측정하여 나타낸 그래프이다.
도 2는 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 단일 또는 복합성분의 처리에 따른 항당화 효과를 측정하여 나타낸 그래프이다.
도 3은 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 단일 또는 복합성분을 인간피부섬유아세포(NHDF, normal human dermal fibroblasts)에 처리하고, 활성산소종 소거 활성을 측정하여 나타낸 그래프이다.
도 4는 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 단일 또는 복합성분을 인간피부섬유아세포(NHDF, normal human dermal fibroblasts)에 처리하고, MMP-1 단백질의 발현을 측정하여 나타낸 그래프이다.
도 5는 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 단일 또는 복합성분을 인간각질형성세포(HaCaT, Human immortalized keratinocyte)에 처리하고, 히알루론산 생성량 변화를 측정하여 나타낸 그래프이다.
도 6은 아이리쉬 모스 추출물, 참산호말 추출물 및 아세틸헥사펩타이드-8의 단일 또는 복합성분을 인간피부섬유아세포(NHDF, normal human dermal fibroblasts)에 처리하고, 세포 재생 활성을 측정하여 나타낸 그래프이다.1 is a graph showing normal human dermal fibroblasts (NHDF) treated with single or combined components of Irish moss extract, true coral extract, and acetylhexapeptide-8, and measuring cell viability.
Figure 2 is a graph showing the measurement of the anti-glycation effect according to the treatment of single or multiple components of Irish Moss extract, true coral extract, and acetylhexapeptide-8.
Figure 3 is a graph showing the treatment of single or complex components of Irish Moss extract, true coral extract, and acetylhexapeptide-8 to human skin fibroblasts (NHDF, normal human dermal fibroblasts) and measuring the active oxygen species scavenging activity. .
Figure 4 is a graph showing the treatment of Irish moss extract, true coral extract, and single or combined components of acetylhexapeptide-8 to human skin fibroblasts (NHDF, normal human dermal fibroblasts) and measuring the expression of MMP-1 protein to be.
5 is a graph showing changes in hyaluronic acid production after treatment of single or multiple components of Irish moss extract, true coral extract, and acetylhexapeptide-8 to human keratinocytes (HaCaT, human immortalized keratinocyte).
6 is a graph showing normal human dermal fibroblasts (NHDF) treated with single or combined components of Irish moss extract, true coral extract, and acetylhexapeptide-8, and cell regeneration activity measured.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail through examples. Since these examples are intended to illustrate the present invention only, the scope of the present invention is not to be construed as being limited by these examples.
실시예 1. 아이리쉬 모스, 참산호말 및 아세틸헥사펩타이드-8의 복합물의 제조Example 1. Preparation of Complex of Irish Moss, True Coral and Acetyl Hexapeptide-8
1-1. 아이리쉬 모스 추출물의 제조1-1. Preparation of Irish Moss Extract
건조된 아이리쉬 모스 100g을 분쇄한 후 3L의 정제수를 용매로 사용하여 12시간 가온 환류추출한 후, 냉침 시키고, 1.2㎛ 투과 사이즈를 갖는 여과지로 여과하여 여과액을 수득하였다. 수득된 여과액을 감압농축 및 감압 건조로 농축하여 아이리쉬 모스 건조 분말을 제조하였다. After pulverizing 100 g of dried Irish moss, 3L of purified water was used as a solvent for 12 hours of heating and reflux extraction, followed by cooling and filtering with a filter paper having a 1.2 μm permeation size to obtain a filtrate. The obtained filtrate was concentrated under reduced pressure and dried under reduced pressure to prepare Irish Moss dried powder.
1-2. 참산호말 추출물의 제조1-2. Preparation of true coral algae extract
건조된 참산호말 100g을 분쇄한 후 3L의 정제수를 용매로 사용하여 12시간 가온 환류추출한 후, 냉침 시키고, 1.2㎛ 투과 사이즈를 갖는 여과지로 여과하여 여과액을 수득하였다. 수득된 여과액을 감압농축 및 감압 건조로 농축하여 참산호말 건조 분말을 제조하였다.After pulverizing 100 g of the dried true coral malt, it was heated and refluxed for 12 hours using 3 L of purified water as a solvent, then cooled and filtered with a filter paper having a 1.2 μm permeation size to obtain a filtrate. The obtained filtrate was concentrated under reduced pressure and dried under reduced pressure to prepare a dried powder of true coral powder.
1-3. 아이리쉬 모스, 참산호말 및 아세틸헥사펩타이드-8의 복합물의 제조1-3. Preparation of a complex of Irish moss, true coral and acetyl hexapeptide-8
실시예 1-1 및 1-2에서 제조한 아이리쉬 모스 추출물과 참산호말에 아세틸헥사펩타이드-8을 아래 [표 1]의 중량 비율로 혼합하여 3종 성분으로 구성된 제조예 1 내지 제조예 7의 복합 추출물을 제조하였다. 비교 실험을 위하여 비교예 1 내지 3의 각각의 단일 성분들을 준비하였다. Acetylhexapeptide-8 was mixed with the Irish Moss extract prepared in Examples 1-1 and 1-2 and true coral in the weight ratio shown in [Table 1] below to obtain Preparation Examples 1 to 7 consisting of three components. A complex extract was prepared. For comparative experiments, each single component of Comparative Examples 1 to 3 was prepared.
[표 1][Table 1]
실시예 2. 3종 성분 첨가에 따른 세포 생존 시험Example 2. Cell survival test according to the addition of three components
아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일 또는 복합성분들이 인간 피부섬유아세포(NHDF, normal human dermal fibroblasts)의 생장에 미치는 영향을 아래와 같은 방법으로 확인하였다.The effects of single or combined components of Irish moss extract, true coral and acetylhexapeptide-8 on the growth of normal human dermal fibroblasts (NHDF) were confirmed by the following method.
우선, 40mm 크기의 세포 배양 접시에 10% FBS(fetal bovine serum, Cambrex)가 포함된 전용 배지인 DMEM(Dulbeccos modified Eagles medium) 배지를 이용하여 인간 피부섬유아세포를 1.2×105 농도로 접종하였다. 접종 후 24시간 동안, 37℃, 5% CO2 습윤 조건에서 배양하였다. 이후, 배지를 제거하고 300㎕ 용량의 PBS를 가하고, UVB(UVB Peak range: 312nm, UV dose: 144mJ/cm2)를 조사하였다. First, human dermal fibroblasts were inoculated at a concentration of 1.2×10 5 in a 40 mm cell culture dish using Dulbeccos modified Eagles medium (DMEM) medium containing 10% FBS (fetal bovine serum, Cambrex). For 24 hours after inoculation, 37 ℃, 5% CO 2 It was cultured under humid conditions. Thereafter, the medium was removed, 300 μl of PBS was added, and UVB (UVB peak range: 312 nm, UV dose: 144 mJ/cm 2 ) was irradiated.
UV 처리한 인간 피부섬유아세포에, 무혈청 DMEM 배지에 상기 실시예 1에서 제조한 제조예의 복합성분 시료들을 10배 희석해서 처리하였고, 비교예의 단일성분 시료들을 각각 3.3배 희석하여 처리하였고, 이후 72시간 동안 배양하였다. 72시간 후, 1mg/mL의 MTT를 처리하고 2시간 후, 세포에 MTT 처리로 인해 생성된 포마잔(formazan)을 DMSO로 녹여 570nm에서 흡광도를 측정하였다.UV-treated human dermal fibroblasts were treated with serum-free DMEM medium by diluting the multi-component samples of the preparation example prepared in Example 1 by 10-fold, and the single-component samples of Comparative Example were diluted 3.3-fold, respectively, and then treated with 72 incubated for hours. After 72 hours, 1 mg/mL of MTT was treated, and after 2 hours, formazan produced by MTT treatment was dissolved in DMSO, and absorbance was measured at 570 nm.
실험 결과, 인간 피부섬유아세포에 본 발명의 3종 복합성분을 처리한 경우, 인간 피부섬유아세포의 생존율을 증가시키는 것으로 확인되었으며, 이를 통해 본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 3종 복합성분들이 인간 피부에 안전하게 사용할 수 있음을 확인할 수 있었다(도 1 참조).As a result of the experiment, it was confirmed that when human dermal fibroblasts were treated with the three complex components of the present invention, the survival rate of human dermal fibroblasts was increased. It was confirmed that the three complex components composed of 8 can be safely used on human skin (see FIG. 1).
실시예 3. 항당화 활성Example 3. Antiglycation activity
아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 3종 복합성분이 갖는 항당화(Anti-glycation) 효과를 확인하기 위하여, L-아르기닌(L-arginine)과 포도당을 이용하여 당화 저해 활성을 측정하였다.In order to confirm the anti-glycation effect of the three complex components of Irish moss extract, true coral and acetyl hexapeptide-8, the glycation inhibitory activity was investigated using L-arginine and glucose. measured.
먼저, 1M 인산 완충용액(pH 7.4)을 이용하여 1M L-아르기닌(arginine) 및 1M 포도당을 녹여 준비하고 1M 인산 완충용액을 이용하여 제조예 1 내지 7의 복합성분 시료들을 10배 희석하여 준비하였고, 비교예 1~3의 시료를 단일성분 시료들을 각각 3.3배 희석하여 준비하였다([표 1] 참조).First, 1M L-arginine and 1M glucose were dissolved in 1M phosphate buffer solution (pH 7.4), and the composite component samples of Preparation Examples 1 to 7 were diluted 10-fold using 1M phosphate buffer solution. , Samples of Comparative Examples 1 to 3 were prepared by diluting single component samples by 3.3 times (see [Table 1]).
1M L-아르기닌과 1M 인산 완충용액을 1:4의 비율로 섞은 다음 96-웰 플레이트에 80μl씩 분주하였다. 여기에 각각 50ppm으로 희석한 시료와 양성대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100μl씩 첨가하여 잘 섞어주었다. 그 다음, 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충용액으로 희석한 포도당을 넣은 후, 70℃에서 4시간 동안 반응시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420nm에서 흡광도를 측정하여 당화 정도를 측정하였다.1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1:4, and then 80 μl was dispensed into a 96-well plate. Samples diluted to 50 ppm and 100 μl of 0.01 M aminoguanidine to be used as a positive control were added thereto and mixed well. Next, after adding glucose diluted with 1M phosphate buffer so that the final concentration of glucose is 0.1M, the mixture was reacted at 70° C. for 4 hours. The degree of glycosylation was measured by measuring the absorbance at 420 nm of the 96-well plate using a spectrophotometer.
Glycation 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420nm에서 흡광도를 측정하였다.The glycation experimental group was an experimental group in which 1M L-arginine and 1M glucose were added to induce glycation.
당화 저해율(%)은 하기 [식 1]을 이용하여 계산하였으며, 실험을 3회 수행한 후 평균값을 계산하여 하기 [표 2]에 정리하였다.The glycation inhibition rate (%) was calculated using the following [Equation 1], and after performing the experiment three times, the average value was calculated and summarized in [Table 2] below.
[식 1][Equation 1]
[표 2][Table 2]
상기 [표 2]의 실험 결과를 참조하면, 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 3종 성분이 배합된 제조예 1 내지 7의 항당화 활성이 각각의 단일성분으로 구성된 비교예 1 내지 3의 항당화 활성이 비해 월등하게 우수한 경향을 나타내었다. Referring to the experimental results in [Table 2], the antiglycation activity of Preparation Examples 1 to 7 in which the three components of Irish Moss extract, true coral malt and acetylhexapeptide-8 were combined were comparative examples consisting of each single component The anti-glycation activity of 1 to 3 showed a significantly superior tendency.
또한, 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 3종 성분의 배합비율도 중요한 것으로 나타났는데, 이들 3종 성분이 10:5~15:2.5~7.5의 중량비율로 혼합되는 경우 대표적인 항당화 물질로 알려진 아미노구아니딘과 동등한 수준의 항당화 활성을 나타내는 것으로 확인되었으며, 이들 3종 성분이 10:10:5의 중량 비율로 혼합되는 경우 아미노구아니딘 대비 우수한 항당화 활성을 나타내는 것으로 확인되었다(표 3 및 도 2 참조). In addition, the mixing ratio of the three components of Irish Moss extract, true coral malt, and acetyl hexapeptide-8 was also found to be important. It was confirmed that the antiglycation activity was equivalent to that of aminoguanidine, which is known as an antiglycation substance, and when these three components were mixed at a weight ratio of 10:10:5, it was confirmed that they exhibited superior antiglycation activity compared to aminoguanidine ( see Table 3 and Figure 2).
[표 3][Table 3]
상기와 같은 결과를 통해, 본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 3종 복합성분은 10:5~15:2.5~7.5의 중량비율에서 각각의 단일 성분 대비 항당화에 시너지 효과가 있고, 양성대조군인 아미노구아니딘에 비해 동등 이상의 우수한 항당화 활성을 나타내어 항당화와 관련된 용도로 효과적으로 사용될 수 있음을 확인할 수 있었다. Through the above results, the three complex components composed of Irish moss extract, true coral and acetylhexapeptide-8 of the present invention showed antiglycation compared to each single component at a weight ratio of 10:5 to 15:2.5 to 7.5. It was confirmed that it can be effectively used for anti-glycation-related purposes because it has a synergistic effect and exhibits excellent anti-glycation activity equal to or higher than that of aminoguanidine, a positive control group.
실시예 4. 항산화 활성Example 4. Antioxidant activity
인간 피부 섬유아세포에서 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 3종 복합성분이 갖는 활성산소종(ROS, Reactive Oxygen Species) 소거능을 확인하는 실험을 수행하였다. An experiment was performed to confirm the reactive oxygen species (ROS) scavenging ability of three complex components composed of Irish moss extract, true coral malt, and acetyl hexapeptide-8 in human skin fibroblasts.
실험은 인간 피부 섬유아세포에 UVB(UVB Peak range: 312nm, UV dose: 144mJ/cm2)를 조사한 다음, 실시예 1에서 준비한 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 복합성분(제조예 1 내지 7, 10배 희석)과 이들의 단일성분(비교예 1 내지 3, 3.3배 희석)을 각각 무혈청 DMEM 배지로 희석하여 처리하고 30분 동안 배양하였고, 여기(excitation) 480nm, 방출(emission) 530nm 조건에서 형광도를 측정하여 DCF 형광 강도(DCF fluorescence intensity)를 비교하여 수행하였다. 통계처리는 GraphPad Prism 프로그램을 사용하여 실시하였으며, ANOVA(one-way analysis of variance)를 이용하여 평균값의 유의성을 5% 미만의 한계로 조사하였다.In the experiment, human skin fibroblasts were irradiated with UVB (UVB Peak range: 312 nm, UV dose: 144 mJ/cm 2 ), and then the Irish Moss extract prepared in Example 1, true coral and acetyl hexapeptide-8 complex components (preparation Examples 1 to 7, 10-fold dilution) and their single components (Comparative Examples 1 to 3, 3.3-fold dilution) were diluted and treated with serum-free DMEM medium, respectively, and incubated for 30 minutes, excitation 480 nm, emission ( emission) was performed by measuring fluorescence under 530 nm conditions and comparing DCF fluorescence intensity. Statistical processing was performed using the GraphPad Prism program, and the significance of the average value was examined with a limit of less than 5% using ANOVA (one-way analysis of variance).
실험 결과를 정리한 [도 3]을 참조하면, 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일 성분들이 처리된 비교예 1 내지 3의 시료 처리군들은 각각 15%(비교예 1), 11%(비교예 2), 및 9%(비교예 3)의 활성산소종 소거능을 나타내는 것으로 측정되어 단일 성분들의 항산화 효과는 그리 높지 않은 것으로 측정되었다. 한편, 이들 3종 성분을 조합한 제조예 1 내지 7의 시료 처리군은 각각 2%(제조예 1), 39%(제조예 2), 47%(제조예 3), 53%(제조예 4), 43%(제조예 5), 34%(제조예 6) 및 6%(제조예 7)의 활성산소종 소거능이 측정되어 조합의 시너지 효과가 있는 것으로 관찰되었으며, 10:5~15:2.5~7.5의 중량비율에서 자외선 무처리 음성대조군과 유사한 수준으로 나타나 더욱 개선된 활성산소종 소거 활성이 관찰되었다.Referring to [Figure 3], which summarizes the experimental results, the sample treatment groups of Comparative Examples 1 to 3 treated with single components of Irish Moss extract, true coral and acetyl hexapeptide-8 were 15% (Comparative Example 1) , 11% (Comparative Example 2), and 9% (Comparative Example 3) of active oxygen species scavenging activity was measured, and the antioxidant effect of single components was determined to be not very high. On the other hand, the sample treatment groups of Production Examples 1 to 7 in which these three components were combined were 2% (Production Example 1), 39% (Production Example 2), 47% (Production Example 3), and 53% (Production Example 4), respectively. ), 43% (Preparation Example 5), 34% (Preparation Example 6), and 6% (Preparation Example 7) of reactive oxygen species scavenging activity were measured, and it was observed that there was a synergistic effect of the combination, 10:5 to 15:2.5 At a weight ratio of ~7.5, a level similar to that of the negative control group without UV treatment was observed, and further improved reactive oxygen species scavenging activity was observed.
상기와 같은 실험 결과를 통해, 본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 복합성분은 이들 조합의 시너지 효과가 10:5~15:2.5~7.5의 중량비에서 극대화되어 항산화 활성이 더욱 개선되는 것으로 분석되었다.Through the above experimental results, the complex components composed of Irish Moss extract, true coral malt and acetyl hexapeptide-8 of the present invention maximized the synergistic effect of these combinations at a weight ratio of 10:5 to 15:2.5 to 7.5, resulting in antioxidant It was analyzed that the activity was further improved.
실시예 5. 피부 주름개선 활성Example 5. Skin wrinkle improvement activity
아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일성분 또는 이들의 복합성분들이 MMP-1 유전자 발현에 미치는 영향을 분석하였다.The effects of single components or complex components of Irish moss extract, true coral malt and acetylhexapeptide-8 on MMP-1 gene expression were analyzed.
실험은 40mm 세포 배양 접시에 2mL의 DMEM 배양액을 넣고, 인간 피부 섬유아세포를 약 1.2x105 농도로 접종한 후, 37℃, 5% CO2 환경에서 24시간 동안 배양하였다. 그 후, 제조예 1 내지 7의 복합성분 시료들을 각각 10배 희석해서 처리한 후 3일간 배양하였고, 비교예 1 내지 3의 단일성분 시료들을 각각 3.3배 희석하여 처리한 후 3일간 배양하였다. 이후 배양액을 회수(harvest)하여 4℃, 7,500rpm 환경에서 5분간 원심분리(centrifuge)하여 ELISA 방법을 이용하여 MMP-1(Human Total MMP-1 kit, R&D Systems, Inc., Minneapolis, MN, USA) 단백질의 발현량 변화를 확인하였다. 모든 실험은 3회 반복하여 측정되었다.In the experiment, 2mL of DMEM culture medium was put in a 40mm cell culture dish, human skin fibroblasts were inoculated at a concentration of about 1.2x10 5 , and cultured for 24 hours in a 37°C, 5% CO 2 environment. Thereafter, the multi-component samples of Preparation Examples 1 to 7 were diluted 10 times and then cultured for 3 days, and the single component samples of Comparative Examples 1 to 3 were diluted 3.3 times and then cultured for 3 days. Thereafter, the culture medium was harvested, centrifuged for 5 minutes at 4°C and 7,500 rpm, and MMP-1 (Human Total MMP-1 kit, R&D Systems, Inc., Minneapolis, MN, USA) was used by ELISA method. ) Changes in protein expression were confirmed. All experiments were measured in triplicate.
실험 결과, 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일성분을 처리한 시험군들의 MMP-1 단백질 발현 억제 효과는 뚜렷하게 나타나지 않았다. 이에 반해 본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 복합성분을 처리한 시험군에서는 MMP-1 단백질 생성량이 현저하게 감소하는 양상을 확인할 수 있었다. As a result of the experiment, the test groups treated with single components of Irish Moss extract, true coral malt and acetylhexapeptide-8 did not clearly show an inhibitory effect on MMP-1 protein expression. On the other hand, in the test group treated with the complex components of the Irish moss extract, true coral malt, and acetylhexapeptide-8 of the present invention, it was confirmed that the amount of MMP-1 protein production was significantly reduced.
실험 결과를 정리한 [도 4]를 참조하면, UVB 조사(144 mJ/cm2)로 증가한 MMP-1 단백질 함량(Con.)을 기준으로, 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일성분 시료를 처리한 시험군은 MMP-1 단백질 발현이 1%, 5% 및 16%로 감소하여, MMP-1 단백질 발현 억제 효과가 미미한 것으로 나타났다. Referring to [Figure 4], which summarizes the experimental results, based on the MMP-1 protein content (Con.) increased by UVB irradiation (144 mJ/cm 2 ), Irish Moss extract, true coral and acetyl hexapeptide-8 In the test group treated with a single component sample, MMP-1 protein expression decreased by 1%, 5% and 16%, indicating that the effect of inhibiting MMP-1 protein expression was insignificant.
이에 반해, 본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 복합성분은 조합 비율에 따라 MMP-1 단백질 발현 억제 효과가 우수한 것으로 나타났는데, 조합 비율에 따라 MMP-1 단백질 발현이 각각 40%(제조예 2), 31%(제조예 3), 60%(제조예 4), 38%(제조예 5) 및 47%(제조예 6)로 측정되어, 10:5~15:2.5~7.5의 중량비율에서 MMP-1 단백질 발현이 효과적으로 억제되는 것으로 관찰되었다.In contrast, the composite of Irish moss extract, true coral malt, and acetylhexapeptide-8 of the present invention was found to have an excellent effect on inhibiting MMP-1 protein expression according to the combination ratio. Measured at 40% (Production Example 2), 31% (Production Example 3), 60% (Production Example 4), 38% (Production Example 5) and 47% (Production Example 6), respectively, 10:5 to 15: It was observed that MMP-1 protein expression was effectively suppressed at a weight ratio of 2.5 to 7.5.
상기와 같은 실험결과를 통해, 본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 복합성분은 이들 조합의 시너지 효과가 10:5~15:2.5~7.5의 중량비에서 극대화되어 피부 세포에서 MMP-1 단백질의 발현을 효과적으로 억제하는 것으로 관찰되었으며, 이를 통해 피부 주름 개선 용도로 효과적으로 사용될 수 있음을 확인할 수 있었다. Through the above experimental results, the complex components composed of Irish moss extract, true coral and acetyl hexapeptide-8 of the present invention maximized the synergistic effect of these combinations at a weight ratio of 10:5 to 15:2.5 to 7.5, It was observed to effectively inhibit the expression of MMP-1 protein in cells, and it was confirmed that it could be effectively used for skin wrinkle improvement.
실시예 6. 피부 보습 활성Example 6. Skin moisturizing activity
본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 복합성분의 피부 보습 효과를 검증하기 위해 이들이 히알루론산(Hyaluronan) 합성 촉진에 미치는 영향을 실험하였다.In order to verify the skin moisturizing effect of the complex components composed of the Irish Moss extract, true coral and acetyl hexapeptide-8 of the present invention, their effect on the promotion of hyaluronan synthesis was tested.
히알루론산(HA, Hyaluronan, Hyaluronic acid)은 주로 표피 각질형성세포와 진피 섬유아세포에 의해 합성되며, 수분과 결합하여 세포가 정상적으로 활동할 수 있는 환경을 조성하는 중요한 역할을 하는 물질이다. 피부에서 히알루론산의 감소는 피부 탄력 저하 및 수분 함유량 감소의 직접적인 원인 중 하나이다. 따라서 본 실험에서는 인간각질형성세포 내에서 히알루론산의 생성량을 확인하였다. Hyaluronic acid (HA, Hyaluronan, Hyaluronic acid) is synthesized mainly by epidermal keratinocytes and dermal fibroblasts, and is a substance that plays an important role in creating an environment in which cells can function normally by combining with moisture. A decrease in hyaluronic acid in the skin is one of the direct causes of a decrease in skin elasticity and a decrease in moisture content. Therefore, in this experiment, the amount of hyaluronic acid produced in human keratinocytes was confirmed.
인간각질형성세포(HaCaT, Human immortalized keratinocyte)를 24 well 세포배양 접시에 1㎖의 배양액을 넣고 약 1×105의 농도로 세포를 접종한 후, 37℃, 5% CO2 환경에서 24시간 동안 배양하였다. 그 후, 상기 실시예 1에 따라 준비된 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일성분(비교예 1 내지 3, 3.3배 희석)과 이들의 복합성분(제조예 1 내지 7, 10배 희석)으로 구성된 시료를 포함한 배지로 교체하여 24시간 배양하였다. 이후 배양액을 회수(harvest)하여 4℃, 7,500rpm 환경에서 5분간 원심분리(centrifuge)한 뒤, ELISA 방법을 이용하여 Hyaluronan(Hyaluronan kit, R&D Systems, Inc., Minneapolis, MN, USA)의 발현량 변화를 확인하였고, 무처리 음성대조군과 비교하여 [도 5]에 정리하였다. Human keratinocytes (HaCaT, human immortalized keratinocyte) were put in 1 ml of the culture medium in a 24 well cell culture dish, and the cells were inoculated at a concentration of about 1×10 5 , and then maintained at 37° C. in a 5% CO 2 environment for 24 hours. cultured. Then, single components (Comparative Examples 1 to 3, 3.3-fold dilution) of Irish Moss extract, true coral and acetyl hexapeptide-8 prepared according to Example 1 and their complex components (Preparation Examples 1 to 7, 10 fold dilution) and cultured for 24 hours. Afterwards, the culture solution was harvested, centrifuged for 5 minutes at 4°C, 7,500 rpm, and the expression level of Hyaluronan (Hyaluronan kit, R&D Systems, Inc., Minneapolis, MN, USA) was used by ELISA method. Changes were confirmed, and compared to the untreated negative control group, summarized in [Figure 5].
실험 결과를 정리한 [도 5]를 참조하면, 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일성분을 시료로 처리한 시험군에서는 무처리 음성 대조군과 비교하여 히알루론산(Hyaluronan)의 생성량이 크게 차이가 없는 것으로 나타났다. 이와 대조적으로 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 복합성분을 처리한 시험군에서는 조합 비율에 따라 히알루론산(Hyaluronan)의 생성량이 농도 의존적으로 증가하는 양상을 확인할 수 있었는데, 10:5~15:2.5~7.5의 중량비율에서 무처리 음성대조군에 비해 각각 141%(제조예 3), 167%(제조예 4), 144%(제조예 5) 및 148%(제조예 6) 증가한 히알루론산의 생성량을 확인할 수 있었다. Referring to [Figure 5], which summarizes the experimental results, in the test group treated with a single component of Irish Moss extract, true coral and acetylhexapeptide-8 as a sample, compared to the untreated negative control group, hyaluronan It was found that there was no significant difference in yield. In contrast, in the test group treated with the complex components of Irish Moss extract, true coral and acetyl hexapeptide-8, it was confirmed that the amount of hyaluronan produced increased in a concentration-dependent manner according to the combination ratio, 10: 141% (Production Example 3), 167% (Production Example 4), 144% (Production Example 5) and 148% (Production Example 6), respectively, compared to the untreated negative control at a weight ratio of 5 to 15:2.5 to 7.5. The amount of hyaluronic acid produced was confirmed.
상기와 같은 결과를 통해, 본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 복합성분은 이들 조합의 시너지 효과가 10:5~15:2.5~7.5의 중량비에서 극대화되어 피부 세포에서 히알루론산(Hyaluronan)의 합성을 효과적으로 증가시키는 것으로 관찰되었으며, 이를 통해 피부 보습 용도로 효과적으로 사용될 수 있음을 확인할 수 있었다. Through the above results, the combination of Irish moss extract, true coral and acetyl hexapeptide-8 of the present invention maximizes the synergistic effect of these combinations at a weight ratio of 10:5 to 15:2.5 to 7.5, so that skin cells was observed to effectively increase the synthesis of hyaluronan, and through this, it was confirmed that it can be effectively used for skin moisturizing purposes.
실시예 7. 피부 재생 활성Example 7. Skin regeneration activity
본 발명의 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8로 구성된 복합성분의 피부 재생 활성을 검증하였다.The skin regeneration activity of the complex component consisting of Irish moss extract, true coral and acetyl hexapeptide-8 of the present invention was verified.
실험은 세포배양 100㎜ 디쉬에 1차 배양 피부 세포인 인간 피부 섬유아세포가 80% 증식했을 때, 멸균된 tip(200ul)의 끝단을 이용하여 피부 세포에 상처를 주고, 실시예 1에서 제조한 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 단일성분을 포함하는 시료(3.3배 희석) 또는 이들의 복합성분을 포함하는 시료(10배 희석)를 각각 주입하였다. 주입 48시간 경과 후, 세포 재생 효과를 확인하였다.In the experiment, when human skin fibroblasts, which are primary cultured skin cells, proliferated by 80% in a 100 mm cell culture dish, the skin cells were wounded using the tip of a sterilized tip (200ul), and the Irish prepared in Example 1 A sample containing a single component of Moss extract, true coral and acetylhexapeptide-8 (3.3-fold dilution) or a sample containing these complex components (10-fold dilution) was injected respectively. After 48 hours of injection, the cell regeneration effect was confirmed.
이때, 세포 증식의 측정은 MTT(methylthiazole-2-yl-2.5-diphenyl tetrazolium bromide) 분석 방법과 디프 퀵 스테인(Diff quic stain) 방법을 이용하여 세포염색 후 현미경으로 확인한 후, 무처리군 대비 세포 재생율을 측정하였다. At this time, the cell proliferation was measured using the MTT (methylthiazole-2-yl-2.5-diphenyl tetrazolium bromide) analysis method and the Diff quic stain method, followed by cell staining and microscopic confirmation, and cell regeneration rate compared to the untreated group was measured.
실험 결과를 정리한 [도 6]을 참조하면, 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 복합성분을 손상된 피부세포에 처리하는 경우, 손상된 피부세포 재생이 직접적으로 촉진되는 것을 확인할 수 있었으며, 이러한 효과는 10:5~15:2.5~7.5의 중량비에서 더욱 우수한 것으로 나타났는데, 구체적으로 무처리 음성대조군에 비해 각각 131%(제조예 3), 152%(제조예 4), 146%(제조예 5) 및 132%(제조예 6) 증가한 세포 재생 활성을 확인할 수 있었다. Referring to [Figure 6], which summarizes the experimental results, when damaged skin cells are treated with the complex components of Irish Moss extract, true coral malt, and acetyl hexapeptide-8, it can be confirmed that regeneration of damaged skin cells is directly promoted. This effect was found to be more excellent at a weight ratio of 10:5 to 15:2.5 to 7.5, specifically 131% (Production Example 3), 152% (Production Example 4), and 146%, respectively, compared to the untreated negative control group. (Preparation Example 5) and 132% (Preparation Example 6) increased cell regeneration activity was confirmed.
상기와 같은 결과를 토대로 아이리쉬 모스 추출물, 참산호말 및 아세틸헥사펩타이드-8의 복합성분이 피부 세포의 재생을 촉진하는 직접적인 효과가 있음을 확인할 수 있었다. Based on the above results, it was confirmed that the complex components of Irish Moss extract, true coral malt, and acetyl hexapeptide-8 had a direct effect of promoting skin cell regeneration.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described specific parts of the present invention in detail above, it is clear that these specific techniques are merely preferred embodiments for those skilled in the art, and the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (5)
항당화용 화장료 조성물.It contains three complex components of Irish Moss extract, true coral extract and acetyl hexapeptide-8 as active ingredients, wherein the three complex components are composed in a weight ratio of 10:5 to 15:2.5 to 7.5,
A cosmetic composition for anti-glycation.
상기 3종 복합성분은 10:10:5의 중량비로 구성된 것을 특징으로 하는,
항당화용 화장료 조성물.According to claim 1,
Characterized in that the three composite components are composed of a weight ratio of 10: 10: 5,
A cosmetic composition for anti-glycation.
상기 3종 복합성분은 활성산소종(ROS, Reactive Oxygen Species)을 소거하고, MMP-1 단백질의 발현 억제를 통해 피부 주름 생성을 억제하며, 히알루론산(Hyaluronan) 합성을 촉진하는 것을 특징으로 하는,
항당화용 화장료 조성물.According to claim 1,
Characterized in that the three complex components scavenge reactive oxygen species (ROS), suppress skin wrinkles by suppressing MMP-1 protein expression, and promote hyaluronan synthesis,
A cosmetic composition for anti-glycation.
상기 3종 복합성분은 피부 상처 재생 촉진 활성을 나타내는 것을 특징으로 하는,
항당화용 화장료 조성물.According to claim 1,
Characterized in that the three complex components exhibit skin wound regeneration promoting activity,
A cosmetic composition for anti-glycation.
항당화용 식품 조성물.It contains three complex components of Irish Moss extract, true coral extract and acetyl hexapeptide-8 as active ingredients, wherein the three complex components are composed in a weight ratio of 10:5 to 15:2.5 to 7.5,
A food composition for anti-glycation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210128268A KR102491017B1 (en) | 2021-09-28 | 2021-09-28 | Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210128268A KR102491017B1 (en) | 2021-09-28 | 2021-09-28 | Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102491017B1 true KR102491017B1 (en) | 2023-01-20 |
Family
ID=85108438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210128268A KR102491017B1 (en) | 2021-09-28 | 2021-09-28 | Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102491017B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240062623A (en) * | 2022-11-02 | 2024-05-09 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040057103A (en) * | 2002-12-24 | 2004-07-02 | 벤트리 주식회사 | Composition for a degenerative arthritis comprising a seaweed extract |
KR101339915B1 (en) | 2013-04-19 | 2013-12-10 | 주식회사 더마랩 | Preparation method for ceratonia siliqua fruit extract and cosmetic composition for anti-aging comprising the same |
KR20170080094A (en) | 2015-12-31 | 2017-07-10 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising 4-(4-Hydroxyphenyl)-2-butanone |
KR20180118563A (en) * | 2017-04-21 | 2018-10-31 | 유씨엘 주식회사 | Nano-emulsion containing peptide and seaweeds extracts and cosmetic composition using the same |
-
2021
- 2021-09-28 KR KR1020210128268A patent/KR102491017B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040057103A (en) * | 2002-12-24 | 2004-07-02 | 벤트리 주식회사 | Composition for a degenerative arthritis comprising a seaweed extract |
KR101339915B1 (en) | 2013-04-19 | 2013-12-10 | 주식회사 더마랩 | Preparation method for ceratonia siliqua fruit extract and cosmetic composition for anti-aging comprising the same |
KR20170080094A (en) | 2015-12-31 | 2017-07-10 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising 4-(4-Hydroxyphenyl)-2-butanone |
KR20180118563A (en) * | 2017-04-21 | 2018-10-31 | 유씨엘 주식회사 | Nano-emulsion containing peptide and seaweeds extracts and cosmetic composition using the same |
Non-Patent Citations (1)
Title |
---|
[네이버 블로그]"볼륨 탄력을 위한 영양크림 메디필 펩타이드9 볼륨 앤 텐션 톡스"(2021.04.02.) 1부.* * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240062623A (en) * | 2022-11-02 | 2024-05-09 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
KR102681194B1 (en) | 2022-11-02 | 2024-07-03 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102301576B1 (en) | Cosmetic composition for whitening and wrinkle improvement, comprising a peptide complex obtained from microalgae extract and a ginsenoside complex obtained from a wild ginseng cultured root extract | |
KR101124971B1 (en) | Cosmetic composition containing Salicornia herbacea callus Extracts and Laminaria digitata Extracts for Improving Skin Wrinkle or enhancing skin Elasticity | |
KR102491017B1 (en) | Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient | |
KR102544792B1 (en) | Composition Comprising Complex Extract of seaweeds Fermented by Lactobacillus Brevis with Anti-Wrinkling and Elasticity, Antioxidant, and Skin Hydration Property as Active Ingredient | |
KR20230110475A (en) | Composition for strengthening skin barrier containing Ganoderma lucidum extract as an active ingredient | |
KR20220162666A (en) | Composition for Skin Whitening, Moisturizing, Strengthening Skin Barrier, Skin Cell Regeneration, and Anti-Wrinkle Property Comprising Fermented Extract of Broussonetia kazinoki as Active Ingredient | |
KR101702042B1 (en) | Cosmetic composition having anti-wrinkle effect containing the Fermented extract of Walnuts, Chestnuts | |
KR102014312B1 (en) | Skin-whitening functional composition including polyopes affinis extracts | |
KR102508319B1 (en) | Cosmetic composition for skin whitening or skin regeneration comprising by-product of Ehwaju | |
KR102181596B1 (en) | Composition for Improving Skin Conditions with Improved Skin Whitening, Antioxidant, and Moisturizing Property Comprising Complex Extract of Aloe vera, Citrus limon, and Citrus nippokoreana | |
KR102226131B1 (en) | Composition for skin moisturizing comprising extract of fermented Setaria italica as effective component | |
KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
KR102168533B1 (en) | Cosmetic composition for whitening or improving the facial color containing herb extracts | |
KR101948661B1 (en) | Cosmetic composition for skin whitening containing magnolia sieboldii extract ripened at low-temperature using bamboo charcoal | |
KR102326086B1 (en) | Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient | |
KR102575303B1 (en) | Composition for Improving Collagen Synthesis Comprising Plant Complex Extracts as Active Ingredients | |
KR102583304B1 (en) | Composition for Anti-glycation, Whitening and Skin Condition Improvement Comprising Plant Complex Extracts as Active Ingredient | |
KR102557210B1 (en) | Composition for Anti-glycation Property Comprising Decurcinol as Active Ingredient | |
KR102329921B1 (en) | Composition for Improving Skin Conditions Extracts of Swallow's Nest Fermented by Novel Strain of Lactobacillus sp. as Active Ingredient | |
KR102366932B1 (en) | Composition with Antioxidant, Anti-Inflammation, Skin Moisturizing, Anti-Wrinkle, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus Softened Petal as Active Ingredient | |
KR102604678B1 (en) | Cosmetic composition having improved skin regeneration effect and moisture and menufacturing methods thereof | |
KR102183480B1 (en) | Composition for Improving Skin Conditions with Anti-Wrinkling, Antioxidant, Moisturizing, and Skin Cell Regeneration Property Comprising Complex Extract of Eucalyptus globulus, Lycium chinense, and Betula platyphylla as Active Ingredient | |
KR101221711B1 (en) | Cosmetic composition containing extract of Cleyera japonica | |
KR102225585B1 (en) | Cosmetic Compositions for Improving Skin Wrinkle Containing Processing Product of Ginseng Steaming Extract | |
KR20170061802A (en) | Composition for skin whitening comprising extract of Castanopsis cuspidata var. sieboldii or Cinnamomum japonicum Siebold |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |